Movair Announces Commercial Launch of Luisa Life Supporting Ventilator with High-Flow Oxygen Therapy
[ad_1]
Extended compliance is critical for patients with chronic and acute respiratory disease who require long-term ventilation. Luisa is designed to help patients live everyday experiences and an active, mobile lifestyle. Luisa weighs only 2.4 kg, has a battery life of up to 18 hours and offers patients eight adjustable comfort settings for personalized, tailor-made therapy.
Luisa also has a 10-inch rotatable display and flexible connectivity options so that patients can integrate the ventilator into current lifestyle habits, such as sleeping on a specific side of the bed. In addition, Luisa can be programmed in multiple languages to ensure that a wide variety of patients, families and caregivers receive understandable alarm notifications.
“The life support ventilation with high-flow therapy with the Luisa device has proven to be a real asset during the recent COVID-19 surge,” said Rami Arfoosh, MD, FCCP, pulmonologist and intensive care practitioner and associate professor of medicine at the Georgia Medical School, AU / UGA medical partnership. “It offered a new option to meet the high flow needs for some patients in their home environment. Otherwise, these patients would have continued to occupy hospital beds because there is a lack of equipment at home that meets their needs. Luisa also offers the unique function of switching between high-flow nasal cannula (HFNC) and non-invasive ventilator (NIV) with different modes at the push of a button. “
Luisa offers respiratory support and uses all standard volume, pressure and mouthpiece ventilation modes with the additional benefit of high-flow oxygen therapy, which can support patients ventilated at night with a less intrusive nasal cannula during the day. High-flow oxygen therapy delivers a mixture of air and oxygen that meets or exceeds the patient’s inspiratory flow needs to improve oxygenation and reduce the work of breathing.
“Increasing patient respiratory illnesses, COVID-19 and product recalls have created a critical need for ventilators in the United States The United States,” called David Shockley, CEO of Movair. “We are responding to this demand with the introduction of Luisa, a portable and compact home ventilation device that is available in. was developed and manufactured Germany, which also offers high-flow oxygen therapy to patients. At Movair, we are committed to advancing life-enhancing respiratory therapies that help patients breathe better and live better. The introduction of Luisa underscores this commitment. “
Luisa is the third generation ventilator developed by Lowenstein Medical in. is developed and manufactured Germany, and marketed in Europe since 2020. It can be prescribed to patients diagnosed with chronic respiratory failure due to chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) if certain requirements are met. Luisa can offer high-flow therapy to patients who need ventilation at home and also offers FIO₂ and SPO₂ monitoring and ventilation from 100 ml VT.
Movair is the exclusive US distributor for Lowenstein Medical. While Luisa can be purchased through various long-life medical device (DME) providers, it is usually provided to patients by these DMEs through private or state health insurance. In August, Movair began pre-marketing Luisa, which is already used by thousands of patients in the United States. Many of these patients are recovering from the COVID-19 infection and have been moved home with Luisa.
For more information about Luisa, pulmonologists, respiratory therapists, nurses, clinical care teams, home health care providers and DMEs can contact Movair at [email protected].
In addition to introducing Luisa, the company also announced a new name and rebranding, coinciding with the company’s renewed focus on strengthening and streamlining its position as an industry-leading provider of innovative respiratory therapy technologies. For almost 30 years, Austin-based Movair, formerly known as International Biophysics Corporation, has designed and manufactured life support devices, including heart pumps, surgical instruments, medical molds, and home medical devices. The company is best known for developing AffloVest, the first fully mobile and battery-powered airway freedom vest in The United States.
Movair is committed to advancing new ventilation solutions that give patients more opportunities to have the day-to-day experiences that their illness makes much more difficult. The company stands ready to accelerate the growth of its respiratory therapies portfolio over the next 12 months.
References
1Lodeserto, F. et al. High-flow nasal cannula: mechanisms of action and indications for adults and children. Cureus. 10 (11): e3639.
About Mōvair
For almost three decades, Movair’s team of ambitious entrepreneurs and visionaries has been developing life-sustaining therapies that redefine treatment strategies and improve patients’ quality of life. With a tradition defined by better breathing, Movair connects patients and clinicians with trustworthy, life-enhancing ventilation technology. By implementing simple but powerful improvements and developing breakthrough advances, Movair enables continuous, effortless and inspired breath. Movair is based in Austin, Texas.
Follow Mōvair on: LinkedIn, Twitter and Facebook
* The Luisa ventilator has not been approved or approved by the FDA. The Luisa ventilator has been approved by the FDA under an EUA and is only approved for the duration of the declaration that circumstances exist that justify the approval of the use of ventilators, ventilation hose connections and ventilation accessories in accordance with Section 564 (b) (1). of Act USC Section 360bbb-3 (b) (1), unless the license is terminated earlier or revoked. This EEA is valid until the statement that there are circumstances justifying the approval of the use of ventilators, breathing tube connections and ventilation accessories during the COVID-19 pandemic is terminated in accordance with Section 564 (b) (2) of the Act, or The EEA is revoked under Section 564 (g) of the Act.
Movair is about to submit an open-ended application 510k FDA approval for Luisa in the fourth quarter of 2021.
SOURCE Movair
similar links
https://www.movair.com
[ad_2]
